Preexisting Antibodies to an F(ab′)(2) Antibody Therapeutic and Novel Method for Immunogenicity Assessment

por Ruppel, Jane, Brady, Ann, Elliott, Rebecca, Leddy, Cecilia, Palencia, Marco, Coleman, Daniel, Couch, Jessica A., Wakshull, Eric
Publicado 2016

Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First‐Line Nonsquamous Non‐Small Cell Lung Cancer...

por von Pawel, Joachim, Spigel, David R., Ervin, Thomas, Losonczy, György, Barlesi, Fabrice, Juhász, Erzsébet, Anderson, Maria, McCall, Bruce, Wakshull, Eric, Hegde, Priti, Ye, Weilan, Chen, Daniel, Chang, Ilsung, Rhee, Ina, Reck, Martin
Publicado 2018

Antibody-mediated activation of the FGFR1/Klothoβ complex corrects metabolic dysfunction and alters food preference in obese humans

por Baruch, Amos, Wong, Chin, Chinn, Leslie W., Vaze, Anjali, Sonoda, Junichiro, Gelzleichter, Thomas, Chen, Shan, Lewin-Koh, Nicholas, Morrow, Linda, Dheerendra, Suresh, Boismenu, Richard, Gutierrez, Johnny, Wakshull, Eric, Wilson, Maria E., Arora, Puneet S.
Publicado 2020

Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First‐Line Metastatic Colorectal Cancer

por García‐Carbonero, Rocío, van Cutsem, Eric, Rivera, Fernando, Jassem, Jacek, Gore, Ira, Tebbutt, Niall, Braiteh, Fadi, Argiles, Guillem, Wainberg, Zev A., Funke, Roel, Anderson, Maria, McCall, Bruce, Stroh, Mark, Wakshull, Eric, Hegde, Priti, Ye, Weilan, Chen, Daniel, Chang, Ilsung, Rhee, Ina, Hurwitz, Herbert
Publicado 2017